Study duration for three-arm non-inferiority survival trials designed for accrual by cohorts

Abstract

Study planning is particularly complex for survival trials because it usually involves an accrual period and a continued observation period after accrual closure. The three-arm clinical trial design, which includes a test treatment, an active reference, and a placebo control, is the gold standard design for the assessment of non-inferiority. The existing statistical methods of calculating minimal sample size for non-inferiority trials with three-arm design and survival-type endpoints cannot take into consideration the accrual rate of patients to the trial, the length of accrual period, the length of continued observation period after accrual closure, and unbalanced allocation of the total sample size. The purpose of this paper is to develop a statistical method, which allows for all these sources of variability for planning non-inferiority trials with the gold standard design for censored, exponentially distributed time-to-event data. The proposed method is based on the assumption of exponentially distributed failure times and a non-inferiority test formulated in terms of the retention of effect hypotheses. It can be used to calculate the duration of accrual required to assure a desired power for non-inferiority trials with active and placebo control. We illustrate the use of the method by considering a randomized, active- and placebo-controlled trial in depression associated with Parkinson’s disease. We then explore the validity of the proposed method by simulation studies. An R-language program for the implementation of the proposed algorithm is provided as supplementary material.

Keywords

Three-arm design non-inferiority trial length survival accrual

Get full access to this article

View all access options for this article.

References

Ellenberg

Temple

. Placebo controlled trials and active-control trials in the evaluation of new treatments. Part 2: practical issues and specific cases. Ann Intern Med 2000; 133: 464–470.

Committee for medicinal products for human use (CHMP) guideline on the choice of the non-inferiority margin. Stat Med 2006; 25: 1628–1638.

Fleming

. Current issues in non-inferiority trials. Stat Med 2008; 27: 317–332.

Kieser

Friede

. Planning and analysis of three-arm non-inferiority trials with binary endpoints. Stat Med 2007; 26: 253–273.

Koch

Röhmel

. Hypothesis testing in the ‘gold standard’ design for proving the efficacy of an experimental treatment relative to placebo and a reference. J Biopharm Stat 2004; 14: 315–325.

International Conference on Harmonization: choice of control group and related design and conduct issues in clinical trials (ICH E10): food and drug administration, DHHS, 2000.

Points to consider on the clinical requirements on modified release products submitted as a line extension of existing marketing authorizations, www.emea.europa.eu/pdfs/human/ewp/187503en.pdf (2003, accessed 4 February 2016).

Note for guidance on clinical requirements for locally applied, locally acting products, containing known constitutions, www.emea.europa.eu/pdfs/human/ewp/023995en.pdf (1995, accessed 4 February 2016).

Temple

Ellenberg

. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: ethical and scientific issues. Ann Intern Med 2000; 133: 455–463.

10.

Committee for Medicinal Products for Human Use (CHMP). Reflection paper on the need of active control in therapeutic areas where use of placebo is deemed ethical and one or more established medicines are available, www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/01/WC500100710.pdf (accessed on 10 February 2012).

11.

Hypericum Depression Trial Study Group. Effect of hypericum perforatum (St John’s Wort) in major depressive disorder. JAMA 2004; 287: 1807–1814.

12.

Pigeot

Schäfer

Röhmel

et al.

Assessing non-inferiority of a new treatment in a three-arm clinical trial including a placebo. Stat Med 2003; 22: 883–899.

13.

Munzel

. Nonparametric non-inferiority analyses in the three-arm design with active control and placebo. Stat Med 2009; 28: 3643–3656.

14.

Hida

Tango

. On the three-arm non-inferiority trial including a placebo with a prespecified margin. Stat Med 2011; 30: 224–231.

15.

Hasler

Vonk

Hothorn

. Assessing non-inferiority of a new treatment in a three-arm trial in the presence of heteroscedasticity. Stat Med 2008; 27: 490–503.

16.

Stucke

Kieser

. A general approach for sample size calculation for the three-arm ‘gold standard’ non-inferiority design. Stat Med 2012; 31: 3579–3596.

17.

Kombrink

Munk

Friede

. Design and semiparametric analysis of non-inferiority trials with active and placebo control for censored time-to-event data. Stat Med 2013; 32: 3055–3066.

18.

Mielke

Munk

Schacht

. The assessment of non-inferiority in a gold standard design with censored, exponentially distributed endpoints. Stat Med 2008; 27: 5093–5110.

19.

Rubinstein

Gail

Santner

. Planning the duration of a comparative clinical trial with loss to follow-up and a period of continued observation. J Clin Epidemiol 1981; 34: 469–479.

20.

Koch

Tangen

. Nonparametric analysis of covariance and its role in noninferiority clinical trials. Drug Inf J 1999; 33: 1145–1159.

21.

Rothmann

Chen

et al.

Design and analysis of non-inferiority mortality trials in oncology. Stat Med 2003; 22: 239–264.

22.

Lange

Freitag

. Choice of delta: requirements and reality – results of a systematic review. Biom J 2005; 47: 12–27; discussion 99–109.

23.

Schwartz

Denne

. A two-stage sample size recalculation procedure for placebo- and active-controlled non-inferiority trials. Stat Med 2006; 45: 3396–3406.

24.

Mielke

Munk

. The assessment and planning of non-inferiority trials for retention of effect hypotheses – towards a general approach. Stat ME 2009.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.19 MB